AOA Dx
Blood Test for Early Detection of Ovarian Cancer
Y CombinatorSummer 2021ActiveHealthcareDiagnosticsHealthcareDiagnosticsWomen's Health
What they do
Problem
Ovarian cancer is often detected too late because there is no reliable early screening test for women.
Solution
AOA Dx is developing a blood test using proprietary glycolipid-based biomarkers to detect early-stage ovarian cancer.
Who it's for
Clinical labs and healthcare providers who screen and manage women at risk for ovarian cancer.
Founders
Oriana Papin-Zoghbi
Founder
CEO & Co-Founder AOA Dx Inc. Passionate about Women's Health.
Alex Fisher
Founder/COO
Chief Operating Officer & Co-Founder of AOA Dx. Passion about improving women's health.
Anna Jeter
Founder
Chief Business Officer & Co-Founder
Company timeline
- Founded2020
- YC batchSummer 2021
- StatusActive
- Team size25 people
- LocationDenver, CO, USA; Cambridge, MA, USA
Similar startups
Morphle Labs
Robotic Automation for cancer diagnostics - Robotic Microscopes &…
X-Zell
Early, pain-free cancer detection.
Clear Gene
Our tests help eradicate cancer by telling doctors whether they got…
Data Driven Bioscience
Cancer Diagnosis 10X faster, 10X cheaper
Freenome
We frequently hear scientists are actively looking for a cure for can…
Guardant Health
Guardant Health is a leading oncology company focused on conquering c…